

Cryo-EM approaches for active-state and inactive-state GPCRs

Ieva Drulyte and Mazdak Radjainia, Thermo Fisher Scientific, Materials and Structural Analysis, Achtseweg Noord 5, 5651 GG Eindhoven, Netherlands

Introduction

Cryo-EM won the 2017 Nobel Prize in Chemistry and has since proven to be game-changing for the structure determination of GPCRs. Cryo-EM doesn't depend on crystallization and enables structure determination of challenging proteins in their native state, which are two significant advantages over existing approaches. As a result, cryo-EM has already become the go-to method for determining active GPCR complexes and is set to overtake crystallography for inactive-state GPCR structures too. Here, we highlight useful tools for robust structure determination of active-state and inactive-state GPCRs.

Figure 1. At the time of writing, there are over 450 GPCR cryo-EM in the Protein Database. Active-state structures grew exponentially after the first structure depositions in 2017. A similar trend is starting to form for fiducial-assisted inactive-state cryo-EM structures following breakthroughs in 2020. Additionally, resolutions of GPCR structures are also continuously improving as high resolution can now be routinely achieved.¹




Figure 2. The scFv16 antibody enables stabilization of receptor complexes with all G-protein subtypes.





Figure 3. CaptureSelect LC-kappa (Human) Affinity Ligand is a VHH that rigidifies Fab fragments.




Enablers of active-state structures

GPCR-Gi/o complex structures mediated by scFv16.

The scFv16 is an antibody fragment that stabilizes GPCR/G-protein complexes by recognizing an interface between Gα and Gβ subunits thereby enhancing the stability of GPCR-Gi/o complexes.²


Figure 4. Structure of the mu-opioid receptor-Gi protein complex.



The scFv16 can also be used for stabilizing Gs and Gq complexes.

The stabilizing effect scFv16 can be transferred to other G-protein subtypes through minimal protein engineering and is therefore broadly applicable for structural studies of GPCR/G-protein complexes.


Figure 5. Structure of the melanocortin receptor 4-Gs complex.



Active-state complexes in the absence of stabilizing antibodies.

Dominant negative Gα protein is an alternative approach for the stabilization of ternary complexes.³ The use of dominant negative mutants is not mutually exclusive with stabilizing antibodies and the combination may facilitate structures of low-efficiency compounds.

Figure 6. Structure of GLP1R using mutant GαS and a 200 kV Glacios cryo-TEM.




Enablers of inactive-state structures

Anti-BRIL Fabs targeting BRIL-fusion GPCRs serve as fiducials for cryo-EM

BRIL-fusions and anti-BRIL Fabs are suited to add rigid mass to GPCRs to overcome the molecular weight barrier of cryo-EM.⁴ AlphaFold2 structure predictions can guide the design of BRIL-fusion constructs towards rigid linker regions.⁵ The LC-kappa VHH helps rigidify anti-BRIL Fabs and increases their fiducial effectivity.


Figure 7. Cryo-EM structure and AF2 prediction of BRIL-fusion Frizzled5 receptor.



Nanobody 6 stabilizes inactive states of GPCRs and can be enlarged with a NabFab.

Nanobody 6 recognizes the inactive-state intracellular loop 3 of the κ-opioid receptor, which can be grafted on other receptors.⁶ Nanobody 6 can be engineered to be engaged by the nanobody-binding NabFab. Further stabilization of the NabFab using the LC-kappa VHH is recommended (not shown).


Figure 8. Inactive-state structure of histamine H2 receptor with a universal nanobody.



Showcase studies featuring inactive-state structures.

When a target-specific Fab is available or when the receptor forms homo-oligomers, inactive structures can be determined directly without needing fusion/chimera approaches.

Figure 9. Showcase studies featuring de novo inactive structure and epitope mapping (left) and tetrameric Salipro®-CXCR4 (right).



Conclusions

- Cryo-EM structures of GPCRs are growing at an exponential rate.
- One-day data collection on 200 kV and 300 kV microscopes is robust for routine resolution at 2.5 Å and below.
- Inactive-state structures are poised to follow the success of active-state structures, benefiting from universal molecular tools and structure prediction-guided construct design.

References

1. Danev R, Belousoff M, Liang YL, Zhang X, Eisenstein F, Wootten D, Sexton PM. Routine sub-2.5 Å cryo-EM structure determination of GPCRs. Nat Commun. 2021 Jul 15;12(1):4333.
2. Maeda S, Koehl A, Matile H, Hu H, Hilger D, Schertler GFX, Manglik A, Skiniotis G, Dawson RJP, Kobilka BK. Development of an antibody fragment that stabilizes GPCR/G-protein complexes. Nat Commun. 2018 Sep 13;9(1):3712.
3. Zhang X, Johnson RM, Drulyte I, Yu L, Kotecha A, Danev R, Wootten D, Sexton PM, Belousoff MJ. Evolving cryo-EM structural approaches for GPCR drug discovery. Structure. 2021 Sep 2;29(9):963-974.e6.
4. Tsutsumi N, Mukherjee S, Waghayr D, Janda CY, Jude KM, Miao Y, Burg JS, Aduri NG, Kossiakoff AA, Gati C, Garcia KC. Structure of human Frizzled5 by fiducial-assisted cryo-EM supports a heterodimeric mechanism of canonical Wnt signaling. Elife. 2020 Aug 7;9:e58464.
5. Zhang K, Wu H, Hoppe N, Manglik A, Cheng Y. Fusion protein strategies for cryo-EM study of G protein-coupled receptors. Nat Commun. 2022 Jul 28;13(1):4366.
6. Robertson, Michael J. and He, Feng and Meyerowitz, Justin G. and Seven, Alpay B. and Panova, Ouliana and Peroto, Maria-Claudia and Che, T. Structure Determination of Inactive-State GPCRs with a Universal Nanobody. bioRxiv 2021.11.02.466983.

Acknowledgements

We thank Dr. David M. Thal (Monash Institute of Pharmaceutical Sciences, Monash University) for the validation of the Invitrogen scFv16.

Trademarks/licensing

© 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. This information is not intended to encourage use of these products in any manner that might infringe the intellectual property rights of others.

Science at a scan
Scan the QR code with your mobile device to visit our Structure-Based Drug Design with Cryo-EM page.

